Vericel Corporation Board of Directors

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Mr. Michael Halpin

Mr. Michael Halpin

Chief Operating Officer

Mr. Patrick J. Fowler

Mr. Patrick J. Fowler

Senior Vice President of Corporate Development & Strategy

Mr. Jonathan D. Siegal

Mr. Jonathan D. Siegal

Principal Accounting Officer, VP & Corporate Controller

Mr. Patrick Helfrich

Mr. Patrick Helfrich

Vice President of Marketing & Commercial Strategy

Mr. Sean C. Flynn

Mr. Sean C. Flynn

Chief Legal Officer

Mr. Eric Burns

Mr. Eric Burns

Vice President of Finance & Investor Relations

Mr. Mike Gilligan

Mr. Mike Gilligan

Senior Vice President of Sales

Comments